# Chronic Inducible Urticaria FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-inducible-urticaria

> No upcoming FDA catalysts in chronic Inducible Urticaria; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for chronic Inducible Urticaria?

No upcoming FDA catalysts in chronic Inducible Urticaria; 3 past events are recorded. ClinicalTrials.gov: "NCT06603220 (A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Evommune, Inc.; Results First Posted 2026-05-19." [Calendar and source filings](https://sec-api.dev/indications/chronic-inducible-urticaria)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06603220?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/chronic-inducible-urticaria#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 8, 2025 | [Oral evo756 300 mg qd primary completion](https://sec-api.dev/pdufa/oral-evo756) | EVMN | Chronic Inducible Urticaria | completed | "NCT06603220 (A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Evommune, Inc.; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603220)) |
| May 11, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Inducible Urticaria | completed | "NCT05976243 (A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05976243)) |
| May 19, 2026 | [Oral evo756 300 mg qd topline data readout](https://sec-api.dev/pdufa/oral-evo756) | EVMN | Chronic Inducible Urticaria | completed | "NCT06603220 (A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Evommune, Inc.; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603220?tab=results)) |

## Drugs

- [Oral evo756 300 mg qd](https://sec-api.dev/pdufa/oral-evo756) (EVMN)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-inducible-urticaria.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Inducible Urticaria FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-inducible-urticaria

```bibtex
@misc{secapidev_indications_chronic_inducible_urticaria_20261116,
  title        = {Chronic Inducible Urticaria FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-inducible-urticaria}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_inducible_urticaria_20261116","title":"Chronic Inducible Urticaria FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-inducible-urticaria","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
